- Home
- FOLD vs BHC Comparison
FOLD vs BHC Comparison
Compare FOLD & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- BHC
- Stock Information
- Founded
- FOLD 2002
- BHC N/A
- Country
- FOLD United States
- BHC Canada
- Employees
- FOLD N/A
- BHC N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- BHC Biotechnology: Pharmaceutical Preparations
- Sector
- FOLD Health Care
- BHC Health Care
- Exchange
- FOLD Nasdaq
- BHC Nasdaq
- Market Cap
- FOLD 2.9B
- BHC 2.5B
- IPO Year
- FOLD 2007
- BHC N/A
- Fundamental
- Price
- FOLD $6.32
- BHC $5.72
- Analyst Decision
- FOLD Strong Buy
- BHC Hold
- Analyst Count
- FOLD 10
- BHC 3
- Target Price
- FOLD $26.89
- BHC $7.00
- AVG Volume (30 Days)
- FOLD 4.2M
- BHC 1.5M
- Earning Date
- FOLD 07-31-2025
- BHC 07-30-2025
- Dividend Yield
- FOLD N/A
- BHC N/A
- EPS Growth
- FOLD N/A
- BHC N/A
- EPS
- FOLD N/A
- BHC 0.27
- Revenue
- FOLD $571,160,000.00
- BHC $9,858,000,000.00
- Revenue This Year
- FOLD $19.97
- BHC $5.53
- Revenue Next Year
- FOLD $22.92
- BHC $3.70
- P/E Ratio
- FOLD N/A
- BHC $21.53
- Revenue Growth
- FOLD 32.29
- BHC 9.91
- 52 Week Low
- FOLD $5.51
- BHC $4.25
- 52 Week High
- FOLD $12.65
- BHC $9.85
- Technical
- Relative Strength Index (RSI)
- FOLD 55.44
- BHC 35.44
- Support Level
- FOLD $6.06
- BHC $5.50
- Resistance Level
- FOLD $6.40
- BHC $7.10
- Average True Range (ATR)
- FOLD 0.28
- BHC 0.26
- MACD
- FOLD 0.01
- BHC -0.13
- Stochastic Oscillator
- FOLD 49.44
- BHC 13.44
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
About BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.